Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database

BACKGROUND: Studies have found an increased risk of pyoderma gangrenosum associated with rituximab. The structural properties and pharmacological action of rituximab may affect the risk of pyoderma gangrenosum. Additionally, pyoderma gangrenosum is associated with autoimmune disorders for which ritu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillen, Jodie Belinda, Stanford, Ty, Ward, Michael, Roughead, E. E., Kalisch Ellett, Lisa, Pratt, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712896/
https://www.ncbi.nlm.nih.gov/pubmed/35933497
http://dx.doi.org/10.1007/s40801-022-00322-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712896/
https://www.ncbi.nlm.nih.gov/pubmed/35933497
http://dx.doi.org/10.1007/s40801-022-00322-6

Ejemplares similares